Vaccinex is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat diseases and conditions with unmet medical needs. Co.'s main platform technologies include: semaphorin 4D (SEMA4D) antibody platform, which is the application of its knowledge of SEMA4D biology to develop its main product candidate pepinemab for the treatment of various indications, including cancer and neuroinflammatory and neurodegenerative diseases; and ActivMAb antibody discovery platform, which is a proprietary human antibody discovery platform based on a method for expressing libraries of human monoclonal antibodies on the surface of mammalian pox viruses. The VCNX average annual return since 2018 is shown above.
The Average Annual Return on the VCNX average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VCNX average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VCNX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|